A number of type 2 diabetes drugs, such as SGLT2 inhibitors, DPP-IV inhibitors, and GLP-1 analogs, are also being investigated for their effects on skeletal muscle mass in T2DM patients and animal models. Here, SLC5A2 is linked to type 2 diabetes mellitus.